Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Skin Neoplasms × talabostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Skin Neoplasms 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 20 Nivolumab 20 aldesleukin 19 Cyclophosphamide 18 Ipilimumab 16 fludarabine 14 Interleukin-2 14 fludarabine phosphate 12 cemiplimab 11 Radiotherapy 7 Biopsy 7 dabrafenib 6 Surveys and Questionnaires 6 Fluorouracil 6 Dacarbazine 6 trametinib 5 Vemurafenib 5 Radiation 5 Blood Specimen Collection 5 Aminolevulinic Acid 5 binimetinib 4 Temozolomide 4 Surgical Procedures, Operative 4 Sirolimus 4 Educational Status 4 sonidegib 3 montanide ISA 51 3 encorafenib 3 avelumab 3 Sodium Chloride 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡